An interventional study of extra corporeal shock wave therapy device in Carpal Tunnel Syndrome, sponsored by Cairo University. Recruiting at 2 sites in Egypt. Open to female participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-11-15.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Carpal Tunnel Syndrome by Cairo University — 9 open to participants now, 10 under way, none of them phase 3. Carpal Tunnel Syndrome · Cairo University.
Among the 21 studies in Carpal Tunnel Syndrome by Cairo University, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is one of 8 that started in 2023, is one of 19 with no phase, and was the 11th registered.
591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.
Browse Carpal Tunnel Syndrome studies →9 of the 21 studies in Carpal Tunnel Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–40
Cairo University · Sites in Egypt
Ages 25–35 · Women only
Cairo University · Sites in Egypt
Ages 20–60
Cairo University · Sites in Egypt
Ages 40–60 · Women only
Cairo University · Sites in Egypt
Ages 25–35 · Women only
By country, each count listing its studies:
Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 40 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 8 started in 2023.
This study's planned enrollment of 68 is above the median of 60 across 446 interventional studies indexed under Carpal Tunnel Syndrome.
Median enrollment 55 across the 20 interventional studies, 119 across the 1 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Carpal Tunnel Syndrome by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sixty eight female patients who had symptoms of carpal tunnel syndromesuch as wrist pain or numbness and paraesthesia and had lymphedema of an upper extremity.Their ages will be ranged from 40 to 60 years. The participants will be selected from Out Patient clinic of Faculty of Physical Therapy, Cairo University and randomly distributed into two equal groups.Duration of treatment for 4weeks.All subjects signed an informed consent form, and the rights of subjects were protected.
In this study the patients will be randomly assigned into two equal groups(34 patients for each group)Group A (experimental group):This group includes 34female patients who will receive extra corporeal shock wave therapy one session per week for 4 weeks in addition to physical therapy exercises (including carpal bone mobilization, nerve glide skin care and manual lymph drainage 2 sessions per week for 4 weeks. Group B (control group):
This group includes 34female patients who will receive shame extra corporeal shock wave therapy one session per week for 4 weeks in addition to physical therapy exercises (including carpal bone mobilization, nerve glide exercises, skin care and manual lymph drainage 2 sessions per week for 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants could be considered and enrolled if they conformed to the diagnosis of CTS, with clinical symptoms for at least 3 months.
The clinical symptoms and signs for the diagnosis of CTS were as follows:
The subject selection will be according to the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group includes 34female patients who will receive extra corporeal shock wave therapy one session per week for 4 weeks in addition to physical therapy exercises (including carpal bone mobilization, nerve glide skin care and manual lymph drainage 2 sessions per week for 4 weeks.
Device: extra corporeal shock wave therapy device
This group includes 34female patients who will receive shame extra corporeal shock wave therapy one session per week for 4 weeks in addition to physical therapy exercises (including carpal bone mobilization, nerve glide exercises, skin care and manual lymph drainage 2 sessions per week for 4 weeks.
Device: extra corporeal shock wave therapy device
Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia. In the control group, sham rESWT just made the same sound without energy emission
Nerve conduction studies
For assessing the motor response, the recorder electrode on abductor pollicis brevis muscle and median nerve was stimulated at wrist region with stimulator electrode, 8 cm proximal to the active electrode , and the distal latency was recorded. Regarding the sensory response, the recorder was fastened on the third finger, and stimulator electrode was placed 14 cm proximal to the recorder and stimulated median nerve at wrist and at palm region, then distal latency was recorded. If only the SNAP distal latency was long, patient had mild CTS, but if both SNAP and CMAP distal latency were long and denervation was not observed in electromyography of APB, it was moderate CTS
Time frame: 4weeks
Limb volume
Upper limb volumes were calculated from circumference measurements taken at 5cm intervals from the dorsum of the wrist to the axilla. Volume was calculated from circumference using the established formula
Time frame: 4weeks
Visual analogue scale (VAS)
The VAS uses a straight 10-centimeter line with one end being 'no pain' and on the other end the 'worst imaginable pain'. The patient chooses a spot on the line then places a perpendicular line to indicate their pain level within the last 24 hours.
Time frame: 4weeks
Boston Carpal Tunnel Questionnaire (BCTQ)
The BCTQ is used to evaluate symptom severity and dysfunction in patients with CTS .It contains 2 measurement scales: a symptom severity scale (BCTQ-S) and a functional status scale (BCTQ-F). The BCTQ-S uses 11 questions to evaluate the intensity and frequency of pain, numbness, weakness and loss of dexterity on a five-point scale ranging from 1 (no symptoms) to 5 (severe symptoms). The results are interpreted as the average scores of the 11 questions. The BCTQ-F has 8 questions to evaluate the level of difficulty in performing daily tasks, each rated on a five-point scale ranging from 1 (no difficulty) to 5 (cannot do at all due to hand or wrist symptoms). The results are interpreted as the average scores of the 8 questions
Time frame: 4weeks
Plan to share: Yes — after 6months we will share the study protocol and informed consent.
Supporting information: Study protocol, Informed consent form
Time frame: after 6 months of study
No publications or documents are linked to this record.
Start is estimated for Nov 2023; primary completion for Dec 2023, 1 month later.
Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 1 month is below that.
Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.